Gynica
Tel Aviv, Israel· Est.
Israeli startup developing vaginal cannabinoid treatments for endometriosis with a microencapsulation delivery platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli startup developing vaginal cannabinoid treatments for endometriosis with a microencapsulation delivery platform.
Women’s HealthGynecologyEndometriosis
Technology Platform
IntraVag© microencapsulation technology for controlled, intra‑vaginal release of cannabinoid APIs, enabling localized treatment with minimal systemic absorption.
Opportunities
First‑to‑market vaginal cannabinoid therapy for endometriosis could capture a large unmet‑need segment in women’s health and enable platform expansion to other gynecological indications.
Risk Factors
Regulatory uncertainty for cannabinoid products, reliance on Phase 1 trial outcomes, and potential competition from emerging non‑hormonal endometriosis therapies.
Competitive Landscape
Differentiates from hormonal and surgical options, as well as systemic cannabinoid products, through localized delivery; competitors include other biotech firms pursuing non‑hormonal endometriosis treatments.